The present investigation was aimed to evaluate the possibility of using diŠerent concentrations and polymeric grades of hydroxypropyl methylcellulose (K4M, K15M and K100M) for transdermal delivery of methotrexate, an immunosuppressant drug for rheumatoid arthritis. The matrixˆlms were evaluated for their physicochemical characterization followed by in vitro and in vivo evaluation. Selected formulations were subjected for their in vivo studies on healthy rabbits following balanced incomplete block design. The relevance of diŠerence in the in vitro dissolution rate proˆle and pharmacokinetic parameters (C max , t max , AUC (s) , t 1/2 , K el , and MRT) were evaluated statistically. The thickness and weight of the patch increased with the increase in polymeric grade and content. Fourier transform infrared spectroscopy and diŠerential scanning calorimetry results conˆrm that there is no interaction between drug and polymer used. X-ray diŠraction study reveals an amorphous state of drug in the matrixˆlms. The in vitro drug release followed Higuchi kinetics (r＝0.972 997; p＜0.001) as its coe‹cient of correlation values predominates over zero order andˆrst order release kinetics. In vitro dissolution proˆles and pharmacokinetic parameters showed a signiˆcant diŠerence between test products ( p＜0.01), but not within test products. A quantitatively good correlation was found between per cent of drug absorbed from the transdermal patches and AUC (s) . A signiˆcant in vitro/in vivo correlation was observed when per cent drug released was correlated with serum drug concentration. Out of the various formulations made, the selected formulations are better in their in vitro dissolution and pharmacokinetic characteristics and thus hold potential for transdermal delivery.
INTRODUCTION
The success of Transdermal Therapeutic System has created much interest in the pharmaceutical industry and has activated research activities related to it. In the present decade, a good number of drugs have been reported for their transdermal applications: scopolamine, nitroglycerin, nicotine, estrogen, testosterone, fentanyl, buprenorphine, lignocaine, clonidine, oxybutynin and diclofenac. 1) These drugs are being investigated and/or developed for transdermal therapeutic system either for academic research or for commercial purpose. 1, 2) Transdermal administration of drugs avoids many of the problems that arise with conventional oral route and with the more invasive methods of drug delivery. Transdermal delivery is best suited for drugs, which display high toxicity and/or narrow therapeutic windows. 1, 3) The present work is aimed at the development of matrix-type transdermal drug delivery system of methotrexate, 4) an antifolate class of antineoplastic agent, which acts by inhibiting the enzyme dihydrofolate reductase. Methotrexate is currently being used as one of the most widely prescribed drugs for the treatment of rheumatoid arthritis (RA) due to its e‹cacy and safety. 5) However, even at low and intermittent doses, oral administration of methotrexate exhibits high inter-individual variability, gastrointestinal and hepatic toxicity. Whereas intravenous route results in systemic toxicity, intraarticular route is painful, and iontophoretic administration causes irreversible damage of skin. 6, 7) Weekly pulse therapy with low dose methotrexate as an immunosuppressant is now theˆrst-line therapy for the treatment of RA not responsive to non-steroidal anti-in‰ammatory drugs alone. 5, 6) Along with weekly pulse therapy, patients are being supplemented with folic acid without compromising the methotrexate e‹cacy. Folic acid/folinic acid is known to inhibit the eŠect of methotrexate. At present its main targets are largely unknown. 8) The low molecular weight (454.5) would theoretically allow the transdermal delivery of the 5 15 mg once a week, to treat RA. Methotrexate in hydrophilic gels with or without penetration enhancer showed promising clinical results. There is insu‹cient information available on factors that might contribute to the skin permeation and systemic delivery of methotrexate suitable for a speciˆc therapeutic need. 8) Treatment of RA required a longer duration, hence the use of chemical penetration enhancers should be restricted in topical formulation of methotrexate, as it may produce some undesired eŠects on skin. The skin enzymes get deactivated in the presence of some penetration enhancers. 9) Moreover, high potency of methotrexate, chronic nature of disease, and inter and intra-patient absorption variability, strongly supports a rationale to develop non-invasive topical delivery system of methotrexate for the treatment of rheumatoid arthritis. An appropriate selection of polymer matrix is necessary in order to develop successful transdermal drug delivery system. The primary objective of the present study was to design and develop a transdermal patch of methotrexate employing varying concentrations of HPMC K4M, K15M and K100M with plasticizer glycerin.
MATERIALS AND METHODS

Materials
Hydroxypropyl methycellulose 
Preparation of Transdermal Films
Matrix type transdermal patches containing methotrexate were prepared using varying concentrations of HPMC K4M, K15M, and K100M individually, keeping drug concentration constant (5 mg/2.25 cm 2 patch). The drug：polymer ratios used were 1：2, 1：3, 1：4, 1： 5, 1：6, and 1：7. The required amount of drug and polymer were dispersed separately in casting solvent (acetone：distilled water in 9：1 ratio) and the polymeric dispersion was sonicated for 2 min, to remove entrapped air bubbles. These two were then mixed and glycerin (150％ w/w of polymer weight) was incorporated as plasticizer. The polymeric dispersion of drug was poured into a glass mould (6 cm×6 cm) fabricated in the laboratory. To control the rate of evaporation of solvent, the mould was covered with a funnel of suitable size. The casting solvent was then allowed to evaporate overnight to obtain the dried lms. Theˆlms were cut into small patches containing equivalent of 5 mg of drug per patch. Backing membrane was then glued and theˆlms were stored between sheets of wax paper in desiccators until further evaluations.
Physicochemical Characterization Thickness The thickness of theˆlms was assessed using digital instrument (FT 1000 Spectralab, India). The polymericˆlm was placed on iron surface and the probe was placed onˆlm surface. The apparatus was calibrated with calibrationˆlm of 103±3 mm (Spectralab, India). The thickness was measured at randomly chosen 5 diŠerent points of each patch in order to ensure uniform thickness.
Weight Variation
The patches were subjected to weight variation by individually weighing ten randomly selected patches. Such determinations were carried out for each formulation.
Film Folding Endurance
This was determined by repeatedly folding of the patches at the same place until it shows any crack or break. The number of times theˆlm could be folded without breaking/ cracking gave the value of folding endurance. Five randomly selected patches of each formulation were tested.
Flatness Longitudinal stripes from the 5 randomly selected medicatedˆlms of each formulation were cut out. The length of each strip was measured, and variations in the length due to non-uniformity of ‰atness were measured. Flatness was calculated by measuring constriction of strips using the formula
Where, l 1 ＝initial length; l 2 ＝cuttedˆlm length 0％ constriction was considered to be 100％ ‰atness.
Content Uniformity Assay of each of the ten randomly selected medicated patches was carried out to determine the drug content. The patch was dissolved in 2 ml of the casting solvent and the volume was adjusted to 100 ml with 0.1N NaOH. The solution wasˆltered, suitably diluted, and content per lm was estimated spectrophotometrically (UV-1700 PharmaSpec, Shimadzu, Japan) at 303.0 nm using standard curve with OD＝0.0522×conc.＋0.0162 (r ＝0.9998; p＜0.001).
Surface pH Theˆlms were kept in contact with 0.5 ml of distilled water for 1 h. The surface pH was measured by means of pH paper placed on the surface of the swollen patch. A mean of two readings was recorded.
Fourier Transform Infrared Spectroscopic Studies A IR Prestige-21 FTIR (Shimadzu, Japan) spectrometer equipped with attenuated total re‰ectance (ATR) accessory was used to obtain the infrared spectra of drug matrix as well as placeboˆlms. Analysis of pure drug, polymers and their physical mixture (in 1：1 ratio) was carried out using diŠuse re‰ec-tance spectroscopy (DRS)-FTIR with KBr. All the powder samples were dried under vacuum prior to obtaining any spectra in order to remove the in‰uence of residual moisture. For each spectrum, 32 scans were obtained at a resolution of 4 cm 
DiŠerential Scanning Calorimetric Studies
Thermal analysis was carried out using diŠerential scanning colorimeter (Q10, TA Instruments, Waters Inc., USA) with a liquid nitrogen cooling accessory. The analysis was performed under purge of dry nitrogen gas (50 cc min -1 ). High purity indium was used to calibrate the heat ‰ow and heat capacity of the instrument. Sample (2.5 5 mg) placed in aluminum crucible cell wasˆrmly crimped with the lid to provide an adequate seal. The sample was heated at from ambient temperature to 250°C at pre-programmed heating rate of 10°C min -1 . All the samples were analyzed in the same manner. In case of two component systems, physical mixtures of individual component (150 mm) in equal weight ratios were prepared in glass mortar and pestle.
X-ray DiŠraction Studies
The X-ray diŠrac-tometer (Regaku-Mini‰ex, Japan) used consisted of 30 kV, 15 mA generator with Cu-Ka radiation anode tube. DiŠraction pattern of pure drug, placeboˆlms and drug loaded matrixˆlms (1：2 ratio) were scanned over 2u range of 2°and 60°at a rate of 2°per min in 0.02°2u step size.
In Vitro Dissolution Studies The in vitro dissolution study of each selected transdermal patch was determined on USP dissolution apparatus equipped with a fractional collector (TDT-08L, Electrolab, India). A Cygnus' sandwich patch holder, a slightly modiˆed form of FDA's sandwich patch holder was used to ensure patch-to-patch reproducibility of transdermalˆlm. 10, 11) The dissolution vessels contained 500 ml of phosphate buŠer pH 7.4 maintained at 32±0.5°C (the skin surface temperature) and paddle speed set at 50 rpm. Patch assembly was carefully placed at the bottom of the vessel and was centered using a glass rod. Five ml sample was withdrawn at one hour time intervals until the completion of drug release. The withdrawn sample was replenished with 5 ml of fresh media.
The withdrawn samples were analyzed for drug content by measuring the absorbance at 303.0 nm using UV-Visible spectrophotometer (UV-1700 PharmaSpec, Shimadzu, Japan). Three such determinations were carried out for each formulation. The content of methotrexate was calculated from the standard curve [O.D.＝0.0525×conc.＋0.0136 (r＝ 0.9997; p＜0.001)]. The in vitro dissolution proˆles, namely, cumulative drug release, dissolution rate constant, and dissolution half life (t 50％ ) were calculated.
Skin Irritation Studies
Skin irritation studies were carried out in the healthy rabbits weighing 1.934 ±0.166 kg. The dorsal surface of the rabbits was cleared and hair was removed by shaving. The patches were placed over the skin with the help of surgical adhesive tape. They were removed after 24 h and the skin was examined for any untoward reaction.
In Vivo Studies The test formulations were tested for their bioavailability on nine healthy rabbits weighing 1.934±0.166 kg following balanced incomplete block design. The protocol of the study in rabbits was approved by the institutional animal ethical committee (Reg. No. 621/02/ac/CPCSEA), Birla Institute of Technology, Mesra, Ranchi, India. The hair of a skin area of around 50 cm 2 was shaved covering both sides of the vertebral column of each rabbit and care was taken to avoid the damage of skin during shaving. The formulation was applied on the shaved surface 24 hours after hair removal. Blood samples were collected from ear vein prior to application ofˆlms and then at 1, 2, 4, 6, 8 and 24 h post application ofˆlms. Due to the small size of the animal and damage to the ear vein, it was not advisable to withdraw the blood for more than the above mentioned intervals. The withdrawn blood sample was set aside for 15 min and then centrifuged for 10 min at 5000 rpm. The supernatant serum samples were stored in well closed tubes under refrigeration (-20°C) until further analysis.
A previously reported spectrophoto‰uorometric procedure with some modiˆcations were used to analyze methotrexate in the serum samples. 12) Acquisition of kinetic data and ‰uorescent measurement were made on a spectro‰uorophotometer (RF 5301 PC, Shimadzu, Japan) equipped with RF-530XPC computer software at l exc ＝375 nm and l em ＝456 nm. Excitation and emission spectra were recorded in a 10 mm quartz cell at ambient temperature conditions. The pharmacokinetic parameters were calculated using non-compartmental pharmacokinetics data analysis software, WinNonlin TM version 5.0.1.
Statistical Evaluations
The relevance of diŠer-ence in the in vitro dissolution rate proˆle and pharmacokinetic parameters was evaluated statistically. The data were tested by two-way analysis of variance.
RESULTS AND DISCUSSION
Matrix dispersion type transdermalˆlms of methotrexate were prepared using varying ratio of drug：polymer (HPMC K4M, K15M and K100M) to get the desired drug release proˆle. The thickness, weight variation, and drug content values of the formulations made are shown in Table 1 . Irrespective of the grade and concentration of HPMC used, the drug content per patch was found within 4.896 to 4.972 mg per patch, but the thickness and weight of the patch increased with the increase in polymer content. The results of ‰atness study showed that none of the formulations had the diŠerence in the strip lengths before and after longitudinal cut, indicating 100％ ‰at-ness, and thus they could maintain a smooth surface when applied onto the skin. Folding endurance values of matrixˆlms found more than 250 indicating good strength and elasticity, which is explained by the linear nature of the cellulose structure. The surface pH of all formulations was in the range of 5.5 6.0, the pH range of skin and hence no skin irritation was expected. Amongst the various formulations made, using diŠerent concentrations and grades of HPMC, six formulations (A F) were selected on the basis of drug content and release pattern for their in vivo studies.
Drug Polymer Compatibility Study Apart from physical characteristics, compatibility between a drug and polymer is a factor in determining the eŠective-ness of polymeric delivery systems. Herein to consider compatibility between polymer and drug we refer to solubility and/or interaction with no alteration in the chemical structure of the polymer or the drug. 13) Because each drug has its own characteristic chemical and physical properties, no delivery vehicle prepared from a particular polymer will serve as universal carrier for all drugs. The possible drug-polymer interaction was studied by Fourier transform infrared spectroscopy (FT-IR), diŠerential scanning calorimetry (DSC) and X-ray diŠraction (X-RD) analysis of pure substances, placeboˆlms and drug loaded matrixˆlms.
Fourier Transform Infrared Spectroscopy The DRS-FTIR spectrum of physical mixture of drug： polymer (1：1) compared with individual spectrum of HPMC K15M and pure MTX (Fig. 1) . The DRS-FTIR spectral analysis of methotrexate showed the principal peaks at about 1693 cm -1 (-COOH), 1643 cm -1 (-CO-NH), 1539, 1500 cm -1 (aryl system), and 831 cm -1 (aromatic ring system) conˆrm-ing the purity of the drug as per established standards. 14, 15) The DRS-FTIR spectra of physical mixture seemed to be only a summation of drug and HPMC K15M spectra. The DRS-FTIR spectrum of physical mixture, showed the major peaks which correspond to drug and polymer respectively.
Further, the ATR-FTIR spectra of drug loaded matrixˆlms prepared from varying grade of HPMC polymers were compared with individual spectrum of placebo polymericˆlms and pure MTX (Fig. 2) . ATR is quick and non-destructive sampling technique for obtaining the IR spectrum of materials surface. 16) This technique required minimum, or no, sample preparation, but an intimate optimal contact between the sample and the ATR crystal is crucial. ATR-FTIR spectra of placebo HPMCˆlms gave the characteristic peaks for HPMC at about 1643, 1109 and 1033 cm -1 vibration region. In the drug loaded matrixˆlms the characteristic peaks for HPMC and MTX were preserved. In theˆlms the intensity of peaks corresponding to drug were reduced, may be due to the inhibition of the methotrexate crystal growth. The reduction in peak intensity and broadening may occur due to change of crystalline nature of drug to amorphous state, which is in agreement with those reported by Kotiyan and Vavia. 17) Formation of amorphous state of drug in matrixˆlm was further veriˆed by X-ray diŠraction analysis. As the characteristic peaks of drug and polymer were preserved in the physical mixture and matrixˆlms, particularly in theˆngerprint region, and also no new peaks were found, no interaction is inferred. These results are in agreement with our earlier work reported in literature. 18) In this study, it has been observed that there is no chemical interaction between methotrexate and polymers used. Some changes in the peaks are observed, which indicate that there may be some physical interaction related to the formation of weak to medium intensity hydrogen bonding between polymers and drug, but in vitro release studies showed that this type of interaction did not interfere with the release of drug from diŠerent grades of HPMC polymer matrix.
DiŠerential Scanning Calorimetry
The DSC was used in order to detect formulation incompatibilities resulting from drug: polymer interactions. The thermograms of the pure drug, pure polymer (HPMC K4M, K15M, and K100M) and their physical mixtures at 1：1 ratio are shown in Fig. 3 . In pure methotrexate, a broad endothermic eŠect was observed over a temperature range of 40 145°C may be due to hydrate form of MTX. 14) A broad endothermic peak, due to the dehydration process was also observed over a temperature range of 60 120°C for all grades of HPMC polymers. Such dehydration endotherm was also observed in case of binary physical mixture. Further, in the binary mixtures, the drug melting signal was clearly distinguishable (Fig. 3) . On the other hand pure HPMC polymers did not show any endothermic peak in this region. Since no new endothermic events were observed in physical mixture, one can state that no incompatibility was found between drug and polymer used. This study indicates that, these polymeric grades are well established in formulating matrix type patches because of their compatibility. 19) X-ray DiŠractometry X-ray diŠraction of pure drug, placeboˆlms and drug loaded matrixˆlms are shown in Fig. 4 . In the matrixˆlms the drug and polymer was used in the ratios of 1：2. The X-ray diŠractogram illustrates the crystalline nature of methotrexate. Numerous distinctive sharp peaks occurred for methotrexate at approximately 2u angles of 28, 29, 39 and 45 degrees. Placeboˆlms made up of diŠerent grades of HPMC exhibited just one broad peak with low intensity at 2u 10 35° (Fig. 4) , and drug loaded matrixˆlms also illustrate a similar broader peak, with lessened intensity. This indicates an almost amorphous state of these polymers and drug. The nature of the drug and change of its physical state from crystalline to amorphous also indicates that the drug was well dispersed in the polymeric matrixˆlms.
In Vitro Dissolution From the in vitro dissolution proˆle data, kinetics of drug release was found 
Values in parentheses indicate±SD (n＝3). K 0 ＝zero-order; K 1 ＝ˆrst-order; and K H ＝Higuchi-type dissolution rate constant; K-P Korsmeyer-Peppas exponential (n) values.
for zero-order (K 0 ),ˆrst-order (K 1 ) and Higuchitype (K h ) release kinetics. Korsmeyer-Peppas semiempirical model were also employed, in order to better characterize the drug release behavior. 20) M t /M ∞ ＝k t n Where, M t /M ∞ is the fractional release of drug in time t, k is a constant incorporating structural and geometric characteristics of the controlled-release device, and n (the release exponent) is a parameter indicative of mechanism of drug release.
The coe‹cient of correlation of each of these release kinetics were calculated and compared ( Table  2 ). The data revealed that the release pattern of formulations are bestˆtted for Higuchi kinetics equation as the formulation coe‹cient of correlation values predominates over zero-order andˆrst order release kinetics. A signiˆcant linear correlation (0.972 0.997, p＜0.01), was found for Higuchi-type release kinetics. This complies with Higuchi's equation for drug release from a matrix; a slow and controlled release was observed, indicating that the drug-release mechanism was by diŠusion, as proposed by Higuchi. Based on Korsmeyer-Peppas semi-empirical model, the bestˆtting was obtained with n0.5, indicating a Fickian release mechanism. In swellable systems, factors aŠecting the release kinetics are liquid diŠusion rate and polymeric chain relaxation rate. When the liquid diŠusion rate is slower than the relaxation rate of the polymeric chains, the diŠusion is Fickian; whereas when the relaxation process is very slow as compared to the diŠusion, the case II transport occurs. When liquid diŠusion rate and polymer relaxation rate are of the same order of magnitude, anomalous or non-Fickian diŠusion is observed. 21) On the basis of these considerations, it is clear that the drug released from our formulations is controlled by polymer chain relaxation. This observation thus supports the results obtained with Higuchi's equation which shows that the patches released the drug by diŠusion-dominated mechanism.
The observed initial burst release in formulations may be accounted to the direct exposure of the matrix lms to the dissolution media. A quick release of the drug present at the surface occurs and such an initial rapid release is attributed to the fact that polymeric matrix may form loose channels within the network because of its hydrophilic nature and the dissolution of hydrophilic drug during the diŠusion process. The observed initial release may be helpful to achieve the therapeutic plasma concentration of the drug in a short time along with a constant release rate for a longer period of time. Initial burst release was higher in matrixˆlms, formulated using low viscosity grade polymer (HPMC K4M), compared to higher viscosity grade polymer (HPMC K15M and HPMC K100M). Due to initial burst eŠects, low dissolution half life (t 50％ ) was found in case of transdermalˆlms formulated with HPMC K4M. t 50％ values increases linearly with increase in concentration and viscosity grade of polymer.
The dissolution rate constant was calculated for all six products of each polymeric grade and compared ( Table 2 ). The dissolution rate constant and t 50％ data showed a signiˆcant diŠerence between the test products ( p＜0.01), but not within the test products ( p＞0.1), indicating that the six sets of data diŠer signiˆcantly. Hence, it can be inferred that the products are not same in their formulations. On the basis of physico-chemical characterization and in vitro release proˆle, six formulations were selected for their comparative in vivo studies.
In Vivo Studies in Rabbits The skin irritation study indicated that neither the polymer nor the drug caused any noticeable irritation or in‰ammation on or around the patch area either during the period of study or after removal of the patch.
For a comparative bioavailability study, serum data between all test products were considered. The pharmacokinetic parameters: C max , t max , AUC (s) , t 1/2 , K el , and MRT data are shown in Table 3 . The mean plasma concentration versus time proˆles of all six test products (A F) are depicted in Fig. 5 . On the basis of plasma half life, AUC( 0 24 and 0 ∞ ) and MRT values, the test products could be ranked as follows: F ＞E＞D＞C＞B＞A ( Table 3 ). The calculated parameters indicate that the biological half life (t 1/2 ) of methotrexate is prolonged from 4 10 h 7) to 17.07 ±2.37 h (transdermal) in rabbits. Hence, the drug administered through transdermal patch will remain for longer period of time in the body and thus exert a sustained the action. The signiˆcantly less elimination rate constant 0.040±0.005 h -1 and high mean residence time values 11.97±0.73 h of methotrexate, further supports the sustained action of the drug from transdermal patches. The high AUC(s) values observed with the patches also indicate increased bioavailability of the drug, this may be due to bypass of the hepaticˆrst pass eŠects and avoidance from gastric degradation. These results are in accordance with theˆndings reported earlier. 22, 23) Upon statistical evaluation (two-way ANOVA), a signiˆcant diŠerence ( p＜0.01) was observed between the test products but not within the test products ( p＞0.1), when AUC (0 12) , AUC (0 24) , AUC (0 ∞) , t 1/2 , K el , and MRT data generated from serum were taken into consideration, except for C max , where no signiˆcant diŠerence ( p＞0.1) was observed. Spearman rank correlation, a non parametric statistical test, 24) demonstrated a high degree of positive correlation, showing a complete agreement in the order of ranks between percentage of drug absorbed from patches and AUC (0 24) ( p＜0.02; two tail) and AUC (0 ∞) (p＜0.02; two tail). The increase in the amount of drug absorbed was thus associated with the increase in blood level and area under the plasma concentration curve (extent of absorption). This was A signiˆant in vitro/in vivo correlation was observed when per cent of drug released at a given time is correlated with plasma drug concentration. There was a point to point relationship between in vitro data and in vivo input rate of drug from the doasge form. A good correlation was observed when per cent drug released was correlated with plasma drug concentration obtained from test product A (r＝0.963; p＜ 0.05), B (r＝0.952; p＜0.05), C (r＝0.921; p＜0.1), D (r＝0.967; p＜0.05), E (r＝0.950; p＜0.05), and F (r＝0.975; p＜0.05) (Fig. 6) .
CONCLUSION
The results of this study indicate that, polymeric grades of hydroxypropyl methylcellulose used have excellentˆlm forming ability. Amongst the polymeric-matrix type transdermalˆlms of methotrexate, prepared with the diŠerent grades and ratios of HPMC and evaluated, test products A, B, C, D, E and F are better in their in vitro dissolution and pharmacokinetic characteristics, and thus hold potential for transdermal delivery. A slow and controlled release of drug is indicated by the fact that the per cent cumulative amount of drug release versus square root of time is found to be linear, thus supporting that the test products are suitable for transdermal lms. FT-IR and DSC studies indicated no interaction between drug and polymer. The drug was distributed uniformly in the matrix and showed an amorphous nature which was conˆrmed using X-RD study. Further, the selected formulations, which have been duly screened, may be evaluated for their pharmacokinetic proˆles in human to the best of their advantage.
